Clearmind Medicine Inc. (CMND) stock
Close on Nov 11, 2026Market cap $782.48KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $782.48K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$30.35
- Diluted shares
- 2M
Trading
- Previous close
- $5.09
- Open
- $5.42
- Day's range
- $4.93 – $5.58
- Volume
- 5,738
- Average volume (20 days)
- 6,552
- Beta (5 years)
- -1.76
- 52-week range
- $4.93 – $2171.84
- RSI (14 days)
- 27.9
- Volatility (1 year)
- 165.8%
- Relative volume
- 0.09×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CMND | S&P 500 | Difference | CMND per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.8% | -2.4% | −22.4 pts | ||
| 3 months | -61.6% | -1.2% | −60.4 pts | ||
| Year to date | -96.6% | +12.3% | −108.9 pts | ||
| 1 year | -99.7% | +12.4% | −112.1 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -92.7% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -92.2% | +11.9% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
EPS, diluted
Free cash flow
Press releases
Releases Clearmind Medicine filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Clearmind Medicine
Pharmaceutical Preparations
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapies for central nervous system disorders. The company's primary focus is on developing 5-methoxy-2-aminoindane (MEAI), an investigational psychedelic substance intended to treat alcohol use disorder, obesity, metabolic disorders, depression, and addiction. Because its therapeutic candidates are currently undergoing preclinical and clinical development, the company has not commercialized any products or technologies and has not generated revenue from product sales.
Company profile, executives and historyClearmind Medicine stock: common questions
What is Clearmind Medicine's stock price?
CMND closed at $4.95 on Nov 11, 2026, down 2.75% on the day. Over the past 52 weeks it traded between $4.93 and $2171.84.
What is Clearmind Medicine's market cap?
Clearmind Medicine was worth $782.48K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CMND's P/E ratio?
Clearmind Medicine lost money over fiscal 2025 (diluted EPS -$30.35), so it has no meaningful P/E ratio.
Does Clearmind Medicine pay a dividend?
No. Clearmind Medicine has not paid a cash dividend over the last twelve months.
How has CMND stock performed over the past year?
Including dividends, CMND returned -99.7% over the past year, against +12.4% for the S&P 500.
Who are Clearmind Medicine's competitors?
Companies most similar to Clearmind Medicine by business, industry and size include PBM, MTRI, NERV, RLMD, NGEN.
See a number that looks wrong?